Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
521.00
0.00 (0.00%)
At close: Jun 27, 2025, 4:00 PM
521.04
+0.04 (0.01%)
Pre-market: Jun 30, 2025, 8:00 AM EDT
Regeneron Pharmaceuticals Stock Forecast
Stock Price Forecast
The 22 analysts that cover Regeneron Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $839.91, which forecasts a 61.21% increase in the stock price over the next year. The lowest target is $547 and the highest is $1200.
Price Target: $839.91 (+61.21%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Regeneron Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 6 | 7 | 6 |
| Buy | 12 | 13 | 12 | 12 | 11 | 11 |
| Hold | 5 | 5 | 5 | 4 | 4 | 4 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 25 | 26 | 25 | 23 | 23 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $950 → $800 | Buy | Maintains | $950 → $800 | +53.55% | Jun 9, 2025 |
| UBS | UBS | Hold Maintains $633 → $560 | Hold | Maintains | $633 → $560 | +7.49% | Jun 5, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $700 → $650 | Strong Buy | Maintains | $700 → $650 | +24.76% | Jun 2, 2025 |
| BMO Capital | BMO Capital | Buy Maintains $800 → $600 | Buy | Maintains | $800 → $600 | +15.16% | Jun 2, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $958 → $755 | Buy | Maintains | $958 → $755 | +44.91% | Jun 2, 2025 |
Financial Forecast
Revenue This Year
13.67B
from 14.20B
Decreased by -3.77%
Revenue Next Year
14.59B
from 13.67B
Increased by 6.78%
EPS This Year
36.28
from 38.34
Decreased by -5.36%
EPS Next Year
40.51
from 36.28
Increased by 11.63%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 14.9B | 16.5B | 18.0B | ||
| Avg | 13.7B | 14.6B | 16.2B | ||
| Low | 12.4B | 12.6B | 14.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.0% | 20.4% | 23.4% | ||
| Avg | -3.8% | 6.8% | 10.7% | ||
| Low | -12.6% | -7.6% | -2.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 44.47 | 56.21 | 66.61 | ||
| Avg | 36.28 | 40.51 | 49.47 | ||
| Low | 29.78 | 32.28 | 37.92 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.0% | 54.9% | 64.5% | ||
| Avg | -5.4% | 11.6% | 22.1% | ||
| Low | -22.3% | -11.0% | -6.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.